The prostate specific membrane antigen (PSMA) highly expressed on prostate cancer cells and the majority of neovasculature of most solid tumors, and the somatostatin receptor (SSR) highly expressed on neuroendocrine tumors have been successful biomarkers in clinic practices for assisting in both EBRT and RPT in the terms of treatment planning and dosimetry guidance 8, 48. This evidence concerns the gene FOLH1 and prostate cancer.